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DObjective: The study objectivewas to evaluate the long-term (5-year) safety and efficacy of mitral valve surgery
with and without the CorCap cardiac support device (Acorn Cardiovascular, St Paul, Minn) in patients with
dilated cardiomyopathy and New York Heart Association class II–IV heart failure.
Background:The Acorn trial provided a unique opportunity to assess the long-term safety and efficacy of mitral
valve surgery because clinical visits and echocardiograms (read by a core laboratory) were completed for 5 years
of follow-up. Further, this study provided follow-up data on the long-term effect of the CorCap cardiac support
device as an adjunct to mitral valve surgery.
Methods: From the original Acorn trial (n¼ 300 patients), 193 patients were enrolled in the mitral valve repair/
replacement stratum. A total of 102 were randomized to mitral valve surgery alone (control group) and 91 were
randomized to mitral valve surgery with implantation of the CorCap cardiac support device (treatment group).
Patients were followed up for 5 years.
Results: As previously reported, 30-day operative mortality was only 1.6%. At 5 years, the total mortality was
30%with an average annual mortality rate of approximately 6% per year. The effects of mitral valve surgery led
to a progressive decrease in left ventricular end-diastolic and end-systolic volumes, which were highly signif-
icant at all time points. At the end of 5 years, there was an average reduction in left ventricular end-diastolic
volume of 75 mL, which represents a 28% reduction from baseline. During 5 years of follow-up, 29 patients
had recurrent mitral regurgitation and 5 patients underwent repeat mitral valve surgery. The addition of the Cor-
Cap device led to greater decreases in left ventricular end-diastolic volume (average difference of 16.5 mL;
P ¼ .05), indicating that the CorCap device had an additive effect to the mitral valve operation.
Conclusions: This study demonstrates long-term improvement in left ventricular structure and function after
mitral valve surgery for up to 5 years. These data provide evidence supporting mitral valve repair in combination
with the Acorn CorCap device for patients with nonischemic heart failure with severe left ventricular dysfunc-
tion who have been medically optimized yet remain symptomatic with significant mitral regurgitation. (J Thorac
Cardiovasc Surg 2011;142:569-74)Supplemental material is available online.
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The Journal of Thoracic and Calikely because of the contributions of chronic volume
overload to progressive ventricular remodeling,3-5 which
is characterized by the process of ventricular dilatation
and a change from a conical to a spherical shape. Mitral
valve repair (MVr) with ring annuloplasty has been
proposed as a surgical treatment, and several studies have
shown that the procedure is safe and often associated with
long-term benefit and/or survival.6-13 However, these
studies have been retrospective, single-center, or lack core
laboratory echocardiographic long-term follow-up. An ad-
ditional concern is that ring annuloplasty does not fully ad-
dress all of the pathophysiologic mechanisms of functional
MR (eg, ventricular dilation, annular dilation, and leaflet
tethering), whichmay contribute to reports suggesting a var-
iable rate of recurrent MR.14-16
The mitral valve replacement (MVR) stratum of the
Acorn randomized trial provides a unique opportunity to
assess the clinical role of MVr surgery in heart failure.17,18
As reported previously, the study was a multicenter andrdiovascular Surgery c Volume 142, Number 3 569
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ACE ¼ angiotensin-converting enzyme
CSD ¼ cardiac support device
LV ¼ left ventricular
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Dprospective evaluation of 193 patients who had MVr
surgery and annual echocardiograms through 5 years of
follow-up assessed by a core laboratory.19 Further, half of
the patients were randomized to concomitant implantation
of the Acorn CorCap cardiac support device (CSD; Acorn
Cardiovascular, St Paul, Minn), which has been shown in
experimental and clinical studies to improve ventricular
size and shape.20,21 Thus, this study also provides long-
term data on the potential additive benefits of passive
containment with a CSD to MVr surgery.METHODS
The Acorn trial was a prospective, randomized, and controlled evalua-
tion of the CorCap CSD.17,18 The study enrolled 300 patients with dilated
cardiomyopathy and heart failure into 2 strata. Patients who had clinically
significant MR and an indication for MVr surgery were enrolled in the
MVR surgery stratum (n ¼ 193 patients) and then randomized to
treatment (mitral valve [MV] surgery plus CSD, n ¼ 91) or control
(MVr surgery alone, n ¼ 102). Patients without a clinical indication for
MVr surgery were enrolled in the no-MVR surgery stratum (n ¼ 107
patients) and are not discussed further in this report.
Patients were eligible for the MVR stratum if they had New York Heart
Association class II–IV heart failure and were between the ages of 18 and
80 years. All patients had a left ventricular (LV) ejection fraction of 45% or
less and LV dilation (LV end-diastolic dimension  60 mm or an LV
end-diastolic dimension index  30 mm/m2). Patients received an optimal
medication regimen that included an angiotensin-converting enzyme
(ACE) inhibitor (or angiotensin receptor blocker if ACE intolerant) and
a beta-blocker (for at least 3 months). Specific exclusion criteria were sum-
marized previously.17,18 The institutional review board of each center
approved the study protocol and all patients gavewritten informed consent.
Baseline testing included blood tests, transthoracic echocardiogram,
quality of life evaluation with Minnesota Living with Heart Failure ques-
tionnaire and the short-form 36 questionnaire, a 6-minute walk test, and
an exercise test to measure peak oxygen consumption. These tests were fol-
lowed only to the common closing date and were previously reported.18
Randomization to treatment or control groups was stratified by site and
based on random permuted blocks.
MV surgery was performed using standard operative techniques includ-
ing cardiopulmonary bypass and an undersized MV annuloplasty ring
placement or valve replacement. CorCap CSD implant techniques have
been summarized previously.22
The CorCap CSD is a fabric mesh device that is implanted around the
heart to provide circumferential diastolic support and reduce LV wall
stress. In animal models of heart failure, the CSD resulted in benefical
changes in LV structure and function, a decrease in myocyte hypertrophy,
improvements in myocyte shortening, decreased interstitial fibrosis, and
a reversal of fetal gene expression.21,22570 The Journal of Thoracic and Cardiovascular SurgFollow-up evaluation was completed at 3 months, 6 months, and then
annually until 5 years and included data on deaths, hospitalizations, adverse
events, andmajor cardiac procedures. Echocardiogramswere obtained at an-
nual visits and were read by the Core Laboratory at the Mayo Clinic, which
was blinded to clinical and randomization data. All efficacy and safety end
points were analyzed according to the intention-to-treat principle. Cumula-
tive survival curves for the risk of death and the time to recurrent MR and re-
peat MV surgery were constructed according to the Kaplan–Meier method.
For continuous variables, comparisons of changes from baseline to 60
months were evaluated with a longitudinal regression analysis, a mixed
effects model in which follow-up visit was the repeated measure and the
baseline value of the response was considered as a covariate.RESULTS
Patient Population
As previously described,19 the MVR stratum included
193 patients (54% female) with a mean age of 53.4 
12.6 years. Baseline New York Heart Association classes
were II (23.3%), III (71.5%), and IV (5.2%). The etiology
of heart failure was idiopathic cardiomyopathy (60.6%),
valvular heart disease (17.1%), and ischemic heart disease
(6.2%). At baseline, patients had evidence of ventricular re-
modeling with a mean LVend-diastolic volume of 270.1 
100.3 mL, LV end-diastolic dimension of 69.7  8.8 mm,
and LVejection fraction of 23.9%  89%. In addition, pa-
tients demonstrated functional limitations with a Minnesota
Living with Heart Failure questionnaire score of 58.8 
23.9 units, a short-form 36 physical functioning score
of 37.1  22.9 units, a 6-minute walk test of 344.3 
90.4 m, and a peak oxygen consumption of 14.1  4.3
mL $ kg1 $ min1. Optimal medical therapy included
ACE inhibitors (97.4%) and beta-blockers (80.3%).
Baseline severity of MR was measured in 2 different lab-
oratories. Echocardiograms reviewed by the individual
sites’ echocardiography laboratories were used to identify
potential patients. All patients had significant MR (MR
grade  3þ) and a clinical indication for MVR surgery
based on site reading, in conjunction with other studies
such as contrast ventriculograms and transesophageal echo-
cardiograms. All echocardiograms were also read in a cen-
tral core laboratory; these values were used solely for
tracking end points. On the basis of the core laboratory
readings, baseline MR grade was 0 in 14 (7.4%) patients,
1þ in 20 (10.6%) patients, 2þ in 44 (23.3%) patients,
3þ in 49 (25.9%) patients, and 4þ in 62 (32.8%) patients.Mitral Surgery
For the intent-to-treat analysis, 9 of the 193patients did not
undergo MV surgery (5 patients refused, 1 patient died be-
fore surgery, and it was surgically decided for 3 patients).
Most patients (n ¼ 155 patients; 84.2%) received an under-
sized mitral annuloplasty ring (ring size of 28 mm used in
82% of patients). There were 29 (15.8%) patients who un-
derwent MVR including 4 patients who were converted
from repair to replacement at the time of the originalery c September 2011
FIGURE 1. Kaplan-Meir survival curve for the entire group of 193
patients in the MV surgery stratum.
FIGURE 2. (A) Reduction in left ventricular end-diastolic volume
(LVEDV) for the entire group of 193 patients in the mitral valve surgery
stratum. There was aggressive and significant reduction in LVEDV at 1,
2, and 3 years, which remained stable at years 4 and 5 consistent with
reverse remodeling. (B) Reduction in left ventricular end-systolic volume
(LVESV) for entire group of 193 patients in the mitral valve surgery
stratum. Similar to the changes in LVEDV, there was a progressive and sig-
nificant decrease in LVESV at 1, 2, and 3 years, which remained stable at
years 4 and 5.
FIGURE 3. Change in left ventricular ejection fraction (LVEF) for the en-
tire group of 193 patients in the mitral valve surgery stratum. There was an
improvement in left ventricular ejection fraction, which was significant at
18 months and remained so for 5 years.
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Doperation. In the other patients, surgeons chose replacement
if there were primary valvular abnormalities (eg, rheumatic
disease) or when it was believed that repair would not yield
a satisfactory result. DuringMVR surgery, most patients had
preservation of both anterior and posterior chordal structures.
The Kaplan–Meier survival curve for the overall group is
shown in Figure 1. As previously reported, the 30-day oper-
ative mortality was 1.6% (3 deaths). At 5 years, the total
mortality was 30% with an average annual mortality rate
of approximately 6% per year.
Cardiac Structure and Function
The effects of MVr surgery on LV structure and function
are summarized in Figures 2 and 3. There was a progressive
decrease in LV end-diastolic volume (Figure 2, A) and LV
end-systolic volume (Figure 2, B) that was highly signifi-
cant at all time points through 5 years. At the end of the
follow-up, there was an average reduction in LV end-
diastolic volume of 75 mL, which represents a 28% reduc-
tion from baseline. There were also improvements in LV
ejection fraction (Figure 3), which reached statistical signif-
icance at 18 months and remained significantly improved
from baseline at 24, 36, 48, and 60 months.
During 5 years of follow-up, 29 patients had recurrent
MR (defined as 3 or 4þMR by the core echocardiography
laboratory readings) and 5 patients underwent repeat MV
surgery. Figure 4 summarizes the Kaplan–Meier estimate
of the freedom from MR or repeat MV surgery. At 5 years,
the cumulative estimate of 3 to 4þMR or repeat MV surgery
was 19%. There was no difference in overall survival or de-
gree of reverse remodeling between patients with MVr or
MVR at 5 years.The Journal of Thoracic and CaMV Surgery With CSD
The effects of the concomitant implantation of the Cor-
Cap CSD to MV surgery were assessed by comparing the
treatment group (MVr plus CSD) with the control grouprdiovascular Surgery c Volume 142, Number 3 571
FIGURE 4. Kaplan-Meir estimate of freedom from 3/4þmitral regurgitation (MR) or redo mitral valve replacement (MVR) combined.
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D(MVr alone). There was no significant difference in survival
or the frequency of recurrent MR between the treatment and
control groups. Compared with the control group, the treat-
ment group (MV surgery plus CSD) had fewer cardiac
transplants (11 vs 12), fewer LV assist devices (5 vs 6),
and fewer biventricular pacemakers (14 vs 19), but none
of these differences was statistically significant.
The effects of the CSD on LV size and shape are shown in
Figures 5 and 6. For LVend-diastolic volume (Figure 5), the
control group (MV surgery alone) demonstrated a progres-
sive decrease in LV end-diastolic volume, suggesting thatFIGURE 5. Reduction in left ventricular end-diastolic volume for the
control group (no cardiac support device) and treatment group (with car-
diac support device). Treatment group (mitral valve surgery and cardiac
support device) had significantly greater decrease in left ventricular end-di-
astolic volume compared with control (mitral valve surgery alone) through-
out the 5 years of follow-up (P ¼ .05). MVR, Mitral valve replacement;
LV, left ventricular.
572 The Journal of Thoracic and Cardiovascular SurgMV surgery by itself can result in reverse remodeling. How-
ever, the treatment (MV surgery and CSD) group had a sig-
nificantly greater decrease in LV end-diastolic volume that
persisted throughout the 5 years of follow-up (average
difference ¼ 16.5 mL; P ¼ .05), indicating that the CorCap
device had an additive effect to MV surgery. Similar addi-
tive benefits were observed with LV end-systolic volume.
Sphericity index (Figure 6) is a reflection of the shape of
the LV (length/width ratio) so that a higher sphericity index
indicates a more ellipsoidal ventricle. Sphericity index in-
creased in the control group, suggesting that MV surgery
by itself can result in an improvement in LV shape. TheFIGURE 6. Sphericity index for the control group (no cardiac support de-
vice) and treatment group (with cardiac support device). The treatment
group (mitral valve surgery and cardiac support device) had significantly
greater increase in sphericity index when compared to control group (mitral
valve surgery alone) (P ¼ .002). MVR, Mitral valve replacement.
ery c September 2011
TABLE 1. Patients experiencing serious adverse events by treatment
group; mitral valve surgery stratum
MVR stratum
Treatment Control
No. % No. % P value*
Allergic response 4 4.4 1 1.0 .19
Arrhythmia 41 45.1 48 47.1 .89
Bleeding 9 9.9 16 15.7 .29
Hemodynamic compromise 66 72.5 62 60.8 .095
Hepatic compromise 2 2.2 0 0.0 .22
Infection/pneumonia 39 42.9 38 37.3 .46
Myocardial infarction 0 0.0 1 1.0 1.00
Neurologic deficit/stroke 17 18.7 9 8.8 .057
Peripheral thrombus/embolism 3 3.3 2 2.0 .67
Pulmonary compromise 30 33.0 21 20.6 .072
Pulmonary embolism 2 2.2 2 2.0 1.00
Renal compromise 13 14.3 9 8.8 .26
Other 50 54.9 59 57.8 .77
Any of the above SAE 83 91.2 93 91.2 1.00
No. of patients 91 102
MVR, Mitral valve replacement; SAE, serious adverse event. *P values generated
from Fisher’s exact test.
Acker et al Acquired Cardiovascular Diseasetreatment group had a significantly greater increase in sphe-
ricity index that persisted throughout 5 years of follow-up
(average difference ¼ 0.071 units; P ¼ .002), indicating
that the CorCap device had an additive effect to MV
surgery.A
C
DAdverse Events
Table 1 summarizes the number of patients experiencing
a serious adverse event at any time during follow-up. Over-
all, 82.4% of the treatment group and 79.4% of the control
group had a serious adverse event. The number of patients
and types of adverse events were not statistically different
between the 2 groups. There were no clinical cases of con-
striction in any patient. The vast majority of serious adverse
events occurred immediately after surgery and were com-
monly observed in patients undergoing cardiac surgery.DISCUSSION
Treatment options for functionalMR in general have been
limited. There is no consistent evidence that standard med-
ical therapies, including ACE inhibitors and beta-blockers,
have long-term benefit onMR severity or outcomes. Despite
evidence thatMV surgery can reduceMR, broad scale adop-
tion of this intervention has been limited by concerns of
a high perioperative mortality rate, rate of recurrent MR,
lack of long-term benefit on the remodeling process, and
overall survival. The present study directly addressed
many of these concerns and demonstrated that MVr surgery
was safe with a low operative mortality rate, low 5-year re-
current rate of MR (19%), and documented long-term ben-
efits in LV structure and function. Whether these results, inThe Journal of Thoracic and Capatients with primarily nonischemic heart failure, can be
expanded to ischemic cardiomyopathy is unknown.
The MV stratum (MVR) of the Acorn Clinical Trial pro-
vided a unique opportunity to evaluate some of the common
questions regarding the role and clinical impact of MVr/
MVR surgery in patients with heart failure. The strength
of this current data set is that the study was conducted as
a multicenter, prospective trial of 193 patients with heart
failure who had poor ventricular function undergoing MV
surgery, with clinical and core laboratory echocardio-
graphic follow-up extending to 5 years. Principal findings
reported earlier19 included a mortality rate of only 1.6%,
one of the lowest mortality rates of any series.8,10,12
Especially noteworthy is that this perioperative mortality
rate represents the outcome of nearly 30 different centers
(Appendix E1). One-, 2-, and 5-year survivals were
86.5%, 85.2%, and 70%, respectively. MV insufficiency
was reduced from 2.7 at baseline to 0.59 at 18 months. At
5 years, freedom from reoperation for 3 to 4þ MR was
81%. There was strong evidence of reversal of ventricular
remodeling as a result of elimination of MV insufficiency
alone. Specifically, there was a significant decrease in
both LV end-diastolic and end-systolic volume, which re-
mained significant out to 5 years. The sphericity index in-
creased and remained significant out to 5 years, consistent
with a return to a more ellipsoid shape. There was also a sig-
nificant increase in LVejection fraction over baseline, seen
at 18 months and maintained out to 5 years. LV mass
decreased significantly at 2 years.19 Finally, the baseline
New York Heart Association class of 2.8 was reduced sig-
nificantly to 2.2 at 2 years.19 This current report underscores
the shorter term results and documents that the benefits seen
at 2 years are maintained after 5 years.
Recent reports from the Cleveland Clinic suggest that the
recurrence rate of ischemicmitral insufficiency after repair is
in the 30% to 40% range.14,15 Early recurrence of mitral
insufficiency, reported by McGee,14 Mihaljevic,15 and their
colleagues, as well as others, has been noted for patients
with ischemic heart failure after coronary artery bypass sur-
gery and annuloplasty ring. These results stand in contrast to
minimal recurrent MR as reported by Braun and associ-
ates,6,23 who demonstrated that the combination of MVr
with a small complete rigid annuloplasty ring and coronary
artery bypass grafting results in significant decrease of LV
end-diastolic dimensions for up to 4 years after surgery.
In addition, Fattouch and associates24 have recently dem-
onstrated in a randomized study of coronary artery bypass
alone versus coronary artery bypass and MVr that the addi-
tion of MVr improved postoperative New York Heart Asso-
ciation functional class, ventricular remodeling, decreased
pulmonary arterial pressures, and led to a decrease in hospi-
talization for heart failure. These same studies also show
low operative mortality rates for combined MV surgery
and coronary artery bypass procedures in patients withrdiovascular Surgery c Volume 142, Number 3 573
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symptoms.
We25 have recently completed a comprehensive analysis
of echocardiograms from these patients. Compared with pa-
tients without MR recurrence, patients with recurrent MR
had greater distal mitral anterior leaflet angle, greater basal
mitral anterior leaflet angle, greater coaptation depth and
tenting area, larger LV volumes, and worse LVejection frac-
tion. Multivariable analysis identified postoperative distal
mitral anterior leaflet angle as the best predictor of MR re-
currence. These data suggest that tethering of the distal an-
terior leaflet secondary to LV dilation is the primary
mechanism of recurrent MR after mitral annuloplasty in
idiopathic cardiomyopathy.
Importantly, the addition of the Acorn CorCap CSD led
to a significant incremental improvement over MVr alone
in terms of LV size and shape for up to 5 years. When im-
planted as a stand-alone intervention, the CorCap device
has been shown to improve LV structure and function in 3
different models of heart failure.21,26 Moreover, we have
previously reported 3-year follow-up data from the CSD
only stratum of the Acorn trial that showed a statistically
significant effect on a composite end point, a reduction in
major cardiac procedures, and a persistent benefit in LV
structure and function.27 The current 5-year data provide
the first evidence that benefits associated with the CorCap
device are durable and sustained through 5 years of
follow-up. Because the implantation of the CorCap CSD
adds only 20 to 30 minutes of surgery time and minimal ad-
ditional risk, the incremental benefit on LV size and shape
appear to be a valuable adjunct to MV surgery.
In summary, this study demonstrates long-term improve-
ment in LV structure and function after MV surgery, with
and without the addition of the Acorn CSD, for up to 5
years. These data provide evidence supportingMVr in com-
bination with the Acorn CorCap device for patients with
nonischemic heart failure and severe LV dysfunction who
have been medically optimized yet remain symptomatic
with significant MR.References
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DAPPENDIX E1. Clinical Centers
Advocate Christ Medical Center, Hershey, Pa: W. Pae, J.
Boehmer, P. Ulsh, K. McFadden; Royal Victoria Hospital/
McGill University, Montreal, Quebec, Canada: R. Cecere,
N. Giannetti, C. Barber; St Louis University, St Louis,
Mo:A. Aharon, P. Hauptman,M. Jacob; StanfordUniversity
Medical Center/Kaiser Permanente, Stanford, Calif: R.
Robbins, M. Fowler, D. Weisshaar, A. Mullin, K. Town;
University of Alabama at Birmingham, Birmingham, Ala:
J. Kirklin, B. Rayburn, K. Harper; University of Florida/
Shands Hospital, Gainesville, Fla: E. Staples, J. Aranda,
D. Leach; University of Maryland Medical Center, Balti-
more, Md: J. Gammie, S. Gottlieb, J. Marshall; University
of Michigan Hospital, Ann Arbor, Mich: S. Bolling, K.
Aaronson, M. Jessup, P. Obriot; University of Minnesota
Medical Center, Minneapolis, Minn: S. Park, L. Miller, J.
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